Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer.
Authors
Braybrooke, J PRanson, Malcolm R
Manegold, Christian
Mattson, K
Thatcher, Nick
Cheverton, P
Sekiguchi, M
Suzuki, M
Oyama, R
Talbot, D C
Affiliation
Cancer Research UK Medical Oncology Unit, Churchill Hospital, Oxford OX3 7LJ, UK.Issue Date
2003-08